Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications

Oct 19, 2016

OTC Disclosure & News Service

-

Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications

PR Newswire

SAN DIEGO, October 19, 2016

SAN DIEGO, October 19, 2016 /PRNewswire/ --

A Potential Treatment for Cancer and Arthritis in Animals

Entest BioMedical's (OTCPINK: ENTB) wholly owned subsidiary Zander Therapeutics, Inc. announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 ('Small Molecule Modulators of NR2F6 Activity for Animals').

NR2F6 is a molecular switch known as an 'orphan nuclear receptor', which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.

Between 15 million and 20 million dogs are currently kept as pets in the United States. Due to advances in technology and nutrition, the average life expectancy of a dog has increased in recent years. It is estimated that over 35% of the current dog population are age 7 years old or older. With the increase in lifespan of dogs has come an increase in the incidence of cancer among the populations of dogs.

According to the European Society of Veterinary Oncology and other sources, about 50% of dogs over ten years old develop a cancer-related condition at some point. In the United States, about 6 million dogs are diagnosed with cancer each year.

Types of cancers commonly found in dogs include lymphoma, mammary tumors in females, mast cell tumors (which are a form of skin cancer), bone cancer, non-Hodgkin's lymphomas and soft issue sarcomas. Certain breeds of dogs have been shown to have higher rates of cancer; among them are golden retrievers, boxers, cocker spaniels, Saint Bernards, greyhounds, poodles, German shepherds, Rottweilers, Shetland sheepdogs, cocker spaniels, Doberman pinschers, beagles, miniature schnauzers and Shih Tzus.

Similarly, the cancer incidence rate for cats is estimated to be about 70 to 80 per 10,000 cats. Cancer is less common in cats than in dogs, but can be quite aggressive. Among cats, common cancers include lymphomas and tumors of the subcutaneous tissues, especially the complex feline fibro-sarcoma.

Pre-clinical research conducted by Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) indicates that by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis.

"This is Zander's first big step towards creating small molecule therapies that can target the NR2F6 molecule, either inhibiting it to treat cancer or activating it to treat arthritis. Both cancer and arthritis have a huge impact on our pets. There are many milestones to achieve before these therapies are able to treat our pets but, this is a critical first step," said David Koos, Ph.D., CEO of Zander Therapeutics, Inc.

About Zander Therapeutics Inc.:

Zander Therapeutics Inc. is a wholly owned subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary application. Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals. Zander Therapeutics Inc. is the exclusive licensee of Regen BioPharma's NR2F6 small molecule technology for use in veterinary medicine.

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

David Koos serves as Chairman and CEO of Entest BioMedical, Inc., Its wholly owned subsidiary Zander Therapeutics, Inc. and Regen BioPharma, Inc. Zander Therapeutics Inc. is the exclusive licensee of Regen BioPharma's small molecule therapies based on NR2F6 for veterinary medicine. Regen BioPharma owns approximately 20% of Entest BioMedical.

CONTACT INFORMATION

Zander Therapeutics Inc. and Entest BioMedical Inc.

David R. Koos, Ph.D.

Venturebridge@gmail.com

Chairman & Chief Executive Officer

+1-619-702-1404 Phone

+1-619-330-2328 Fax

SOURCE Regen BioPharma Inc. and Entest BioMedical's